The Latest Breaking News from EMA

Manthey Porsche driver Thomas Preining clinched victory in the second race of the Norisring round in the 2025 DTM season.

Interpol cited a concerning rise in demand for unauthorised weight loss drugs and peptide supplements in Europe and other wealthy regions.

Raw material dependency and transport bottlenecks, not just production capacity, are the key challenges facing the EU's radiopharmaceutical sector, according to the European Medicines Agency (EMA).

The company behind the drug donanemab said it will ask regulators to reconsider the decision.

iNGENū CRO leverages global expertise, advanced technology, and strategic funding to overcome rare disease trial challenges.

The warning comes amid reports that unregulated therapies are being offered directly to patients, potentially illegally.

It’s easy to get caught up in market noise, but investing in companies backed by strong fundamentals and long-term growth potential can help investors stay the course even during market volatility. Thus, one could consider adding these three high-conviction pharmaceutical stocks, AbbVie (ABBV), Merck & Co. (MRK), and Bristol-Myers Squibb…

The biotech sector’s AI-driven advancements, personalized medicine demand, and streamlined regulations fuel significant market growth. Hence, investors should consider robust biotech stocks such as Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD). Read on.

Porsche has announced that it will have an expanded presence in the DTM in 2025, with Allied Racing joining incumbent Manthey.